# **Biochemical and Biophysical Research Communications**

#### Peter (P.W.) Andrews

Department of Biomedical Science University of Sheffield Sheffield, UK

#### **Wolfgang Baumeister**

Abteilung Molekulare Strukturbiologie Max-Planck-Institut für Biochemie Martinsried, Germany

#### Ernesto Carafoli

Editor-in-Chief Venetian Institute of Molecular Medicine (VIMM) University of Padova, Italy

## Chin Ha Chung

School of Biological Sciences College of Natural Sciences Seoul National University Seoul Republic of Korea

## Zengyi Chang

Biochemistry and Molecular Biology School of Life Sciences Center of Protein Science Peking University Beijing, China

## Vitaly Citovsky

Department of Biochemistry and Cell Biology State University of New York Stony Brook, NY, USA

## **Bengt Fadeel**

Division of Molecular Toxicology Institute of Environmental Medicine Karolinska Institutet Stockholm, Sweden

## **Barry Halliwell**

Biochemistry Department National University of Singapore Singapore, Singapore

#### Cecilia Hidalgo

Faculty of Medicine University of Chile Santiago, Chile

## Hans Jornvall

Department of Medical Biochemistry and Biophysics Karolinska Institutet Stockholm, Sweden

#### Claude Klee

Laboratory of Biochemistry National Cancer Institute National Institutes of Health Bethesda, Maryland, USA

## **Guido Kroemer**

INSERM, U848 Institut Gustave Roussy Villejuif, France

### William J. Lennarz

Department of Biochemistry and Cell Biology State University of New York at Stony Brook Stony Brook, New York, USA

## Michael Lichten

Laboratory of Biochemistry and Molecular Biology, Center for Cancer Research, National Cancer Institute, US

#### Anders (A.H.) Lund

Biotech Research and Innovation Centre University of Copenhagen Copenhagen, Denmark

## Carlos Martínez-A

Department of Immunology and Oncology National Center for Biotechnology Campus Universidad Autonoma 28049 Madrid, Spain

#### Hisao Masai

Director of Center for Basic Technology Research, Genome Dynamics Project Department of Genome Medicine Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

# Satyajit Mayor

Cellular Organization and Signalling Group National Centre for Biological Science (NCBS), UAS-GKVK Campus Karnataka, India

## Katsuhiko K. Mikoshiba

RIKEN Laboratory for Development Neurobiology, Japan

#### Davis Ng

Temasek Life Sciences Laboratory National University of Singapore Singapore, Singapore

#### James M. Ntambi

Departments of Biochemistry and Nutritional Sciences University of Wisconsin-Madison Madison WI 53706, USA

#### **Sten Orrenius**

Institutet of Environmental Medicine Karolinska Institutet Stockholm, Sweden

## Jacques Pouysségur

UMR 6543 CNRS Centre Antoine Lacassagne Nice, France

#### Igor Stagljar

Department of Molecular Genetics and Biochemistry University of Toronto Toronto, Ontario, Canada

#### Bing Su

Department of Immunology and Microbiology, Shanghai Institute of Immunology, China

## Kiyoshi Takatsu

Department of Immunology Institute of Medical Science University of Tokyo, Tokyo, Japan

## Naoyuki Taniguchi

Systems Glycobiology Research Group RIKEN Global Research Cluster Wako, Japan

## Anna Tramontano

Department of Physics Sapienza University of Rome Rome, Italy

#### Olga Troyanskaya

Department of Computer Science and Lewis-Sigler Institute for Integrative Genomics Princeton University, New Jersey, USA

# Isaac P. Witz

Tel Aviv University Tel Aviv, Israel

Correspondence regarding production may be sent to:

## Biochemical and Biophysical Research Communications, Elsevier Inc.

525 B Street, Suite 1800, San Diego, California 92101-4495, USA Telephone +1 (619) 699-6857, Fax +1 (619) 699-6859, E-mail bbrc@elsevier.com



Cover photo. Hypothetical model of the mechanisms involved in AIF processing and release. Exposure of NSCLC cells to the protein kinase C inhibitors, staurosporine or PKC412, results in a hyperpolarization of the plasma membrane. As a consequence, the hyperpolarization-activated HCN2 channel opens and permits Ca<sup>2+</sup> to enter the cell. Both plasma membrane hyperpolarization and the activation of HCN2 channel are inhibited by Cs<sup>+</sup>. The resulting Ca<sup>2+</sup> elevation in the cytosol also translocates to the intermembrane space of the mitochondria and results in the activation of calpain as well as enhanced ROS formation. The calcium chelator, BAPTA is able to inhibit both calpain activation and ROS accumulation, whereas only the latter is inhibited by NAC and Trolox. AIF is cleaved by mitochondrial calpain-I. This cleavage is prevented by PD150606, a selective calpain inhibitor. Cleaved AIF is released into the cytosol and translocates to the nucleus, where it contributes to chromatin condensation and highmolecular weight DNA fragmentation. Nuclear translocation of AIF can be inhibited by binding to Hsp70 in the cytosol. (BBRC Volume 396, pages 95–100). It is reproduced by kind permission of the authors – Sten Orrenius, et al.